NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Is Down 17.4% After FDA ASCENIV Pediatric Expansion And Legal Scrutiny - Has The Bull Case Changed?
In early May 2026, ADMA Biologics reported first-quarter revenue of US$114.49 million, essentially flat year on year, while net income rose to US$45.33 million and the FDA expanded ASCENIV’s indication to primary humoral immunodeficiency patients as young as two years old.
At the same time, short-seller channel-stuffing allegations and multiple securities-law investigations have raised fresh questions about ADMA’s reported growth quality, governance, and future legal exposure.
We’ll now...